Hold-rated reports

904 tickers rated Hold
NewestHighest Score Ranks all reports in this rating group by score, highest first.
Cmb.Tech NV
CMBT·Industrials
B ★★★Hold
Current$18.35
Target$22.55
Return+22.9%
Aug 30, 2026

Cmb.Tech is executing a cash-rich shift toward zero-emission offshore and ammonia-powered shipping, but a heavy 2027 tanker orderbook threatens the geopolitical spot-rate premium that currently supports its leveraged balance sheet.

Score
75
The Toronto-Dominion Bank
TD·Financials
B ★★★Hold
Current$121.25
Target$135.00
Return+11.3%
Aug 30, 2026

Toronto-Dominion Bank is a formidable, cash-generating oligopoly returning billions via aggressive buybacks and dividends, though investors must accept that regulatory asset caps have fundamentally stalled its U.S. growth engine for the foreseeable future.

Score
75
Deere & Company
DE·Industrials
B ★★★Hold
Current$647.76
Target$537.36
Return-17.0%
Aug 23, 2026

Deere is the undisputed, technologically advanced juggernaut of global heavy machinery, successfully masking a deep agricultural recession with a historic infrastructure boom, but its priced-for-perfection valuation leaves absolutely no margin of safety for new capital deployment.

Score
75
Bath & Body Works, Inc.
BBWI·Consumer Discretionary
B ★★★Hold
Current$18.66
Target$21.44
Return+14.9%
Nov 22, 2026

Bath & Body Works offers attractive cash generation and recovery potential at a depressed valuation, but persistent North American store weakness and leverage could delay a sustainable earnings turnaround.

Score
74
Sociedad Química y Minera de Chile S.A.
SQM·Materials
B ★★★Hold
Current$47.85
Target$57.20
Return+19.5%
Nov 20, 2026

SQM combines low-cost lithium resources and a strong iodine franchise with long-term battery-demand growth, but volatile commodity prices and complex Codelco partnership economics constrain earnings visibility and shareholder returns.

Score
74
Ascendis Pharma A/S
ASND·Healthcare
B ★★★Hold
Current$275.39
Target$291.92
Return+6.0%
Nov 14, 2026

Ascendis Pharma combines exceptional rare-disease drug commercialization with expanding profitability and multiple pipeline catalysts, but its premium valuation and heavy YORVIPATH dependence leave limited room for execution setbacks.

Score
74
Life360, Inc.
LIF·Technology
B ★★★Hold
Current$44.66
Target$53.53
Return+19.9%
Nov 12, 2026

Life360 can compound through family-safety subscriptions, international adoption, and advertising monetization, but powerful platform competitors, stock dilution, and uncertain advertising margins limit valuation upside.

Score
74
Fluor Corporation
FLR·Industrials
B ★★★Hold
Current$46.48
Target$54.08
Return+16.4%
Nov 9, 2026

Fluor's record backlog, net cash position, and aggressive share repurchases support earnings recovery and potential upside, but complex project execution and inconsistent free cash flow limit investment conviction.

Score
74
Lamar Advertising Company
LAMR·Real Estate
B ★★★Hold
Current$155.99
Target$168.30
Return+7.9%
Nov 8, 2026

Lamar Advertising combines scarce billboard locations, expanding digital monetization, and reliable REIT cash distributions, but premium historical valuation and advertising-cycle exposure constrain its near-term risk-reward.

Score
74
Moelis & Company
MC·Financials
B ★★★Hold
Current$56.92
Target$61.92
Return+8.8%
Nov 8, 2026

Moelis offers a high-return independent advisory franchise with substantial dividends and earnings upside from an M&A recovery, but cyclical transaction revenue and recurring equity compensation constrain the margin of safety.

Score
74
Privia Health Group, Inc.
PRVA·Healthcare
B ★★★Hold
Current$24.42
Target$26.37
Return+8.0%
Nov 8, 2026

Privia Health can compound through physician-network expansion and value-based care growth, but high earnings multiples and uncertain cash conversion limit the margin of safety.

Score
74
Callaway Golf Company
CALY·Consumer Discretionary
B ★★★Hold
Current$16.83
Target$19.80
Return+17.6%
Nov 8, 2026

Callaway's focused golf brands, stronger balance sheet, and improving margins support earnings recovery, but competitive product cycles and uncertainty over sustainable cash flow limit near-term upside conviction.

Score
74